The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: A single institutional survey

Journal of Thoracic Oncology

Volumn 1, Issue 5, 2006, Pages 501-

  Velcheti, Vamsidhar ^a   Viswanathan, Avinash ^a   Govindan, Ramaswamy ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Washington University in St Louis School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADVANCED CANCER; BRAIN METASTASIS; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; HEALTH SURVEY; HEMOPTYSIS; HISTOPATHOLOGY; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SQUAMOUS CELL; UNITED STATES; LUNG TUMOR; METASTASIS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES;

EID: 34247231012     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200606000-00023     Document Type: Letter

References (5)

1. Page NC, Read W, Tierney RM, Arquette MA, Picarillo J, Govindan R. The epidemiology of small cell lung carcinoma [Abstract 1215]. Proc Am Soc Clin Oncol 2002;21:305a.
2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.
3. Kelly K, Crowley J, Bunn PA Jr., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218.
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
5. Sandler AB, Blumenschein GR, Henderson T, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599 in ASCO Annual Meeting Proceedings, 2005, Atlanta. J Clin Oncol 2006;23(suppl):LBA4.